The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity
Open Access
- 1 August 2001
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 31 (8) , 2504-2511
- https://doi.org/10.1002/1521-4141(200108)31:8<2504::aid-immu2504>3.0.co;2-c
Abstract
The ectopic expression of Fas ligand (FasL/CD95L) in tissues or tumors induces neutrophil infiltration and the destruction of the tissues or the rejection of tumors. It has been suggested thatthe infiltrated neutrophils are responsible for the latter phenomena. FasL is synthesized as a type II transmembrane protein, and soluble FasL is produced by a proteolytic mechanism from the membrane-bound form. We previously demonstrated that uncleavable membrane-bound FasL of mice induces IL-1β release from inflammatory cells, and suggested that the IL-1β enhances neutrophil infiltration. However, recent papers reported that human soluble FasL is directly chemoattractive to neutrophils in vitro and proposed that the soluble form of FasL is responsible for its inflammatory activity. Therefore, in this report, we investigated which form is responsible for the inflammatory activities of human FasL. We produced tumor cell lines expressing one or both forms of human FasL. Cells expressing both forms or only the membrane-bound form of FasL induced neutrophil infiltration when transplanted into the peritoneal cavity of syngeneic mice, while cells expressing only the soluble form did not. Purified soluble FasL failed to induce neutrophil infiltration in vivo. IL-1β release from inflammatory peritoneal exudate and acceleration of tumor rejection were also mediated by membrane-bound but not soluble FasL. These results indicate that the membrane-bound form of FasL is primarily responsible for its inflammatory activity.Keywords
This publication has 26 references indexed in Scilit:
- Antitumor effect of locally produced CD95 ligandNature Medicine, 1997
- Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 1996
- Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in MiceScience, 1996
- Fas ligand in human serumNature Medicine, 1996
- Fas Ligand-Induced Apoptosis as a Mechanism of Immune PrivilegeScience, 1995
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Fas and Fas ligand: lpr and gld mutationsImmunology Today, 1995
- Human Fas ligand: gene structure, chromosomal location and species specificityInternational Immunology, 1994
- Purification and characterization of the Fas-ligand that induces apoptosis.The Journal of Experimental Medicine, 1994
- Participation of a dominant cytotoxic T cell population defined by a monoclonal antibody in syngeneic anti‐tumor responsesEuropean Journal of Immunology, 1990